Replies to post #313973 on Amarin Corp Plc (AMRN)

[Biobillionair]

8-

HIKMA WILL SLOW DOWN THEIR LAUNCH ANYWAY.

Hikma does not control their launch speed after launch. Scripts will be filled for generics regardless of Hikma’s supply, this includes Amarin voluntary applying max discount to match any pricing differences. Oh don’t take my word for it do some DD. If generic supply isn’t there Amarin supports it based on patient safety.....but the funny thing is those are still calculated as damages.

You are sooooo right....how could this ever lead to a settlement. No doubt Hikma will hire a hot shot Washington firm or a “did you just put your whole business at risk” firm....to fix everything.

BB

[Bouf]

Wrong, a preliminary injunction motion can be filed at any time. Read the rules.

[mrmainstreet]

True but the real damage is being done at the insurance level, whether Hikma launch is slow or not. Much of the progress AMRN made moving Vascepa up the tiers is being lost.